Literature DB >> 25763458

Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays. A Tuberculosis Network European Trials Group Study.

Jean-Pierre Zellweger1, Giovanni Sotgiu, Michael Block, Simone Dore, Neus Altet, Rebecca Blunschi, Matthias Bogyi, Graham Bothamley, Christina Bothe, Luigi Codecasa, Patrizia Costa, Jose Dominguez, Raquel Duarte, Andreas Fløe, Isabelle Fresard, José-María García-García, Delia Goletti, Petra Halm, Doris Hellwig, Eveline Henninger, Helga Heykes-Uden, Liane Horn, Katarzyna Kruczak, Irene Latorre, Geneviève Pache, Heidrun Rath, Felix C Ringshausen, Asunción Seminario Ruiz, Ivan Solovic, Maria-Luiza de Souza-Galvão, Ursula Widmer, Peter Witte, Christoph Lange.   

Abstract

RATIONALE: Latent infection with Mycobacterium tuberculosis is defined by a positive IFN-γ release assay (IGRA) result in the absence of active tuberculosis. Only few, mostly monocentric studies have evaluated the role of IGRAs to predict the development of tuberculosis in recent contacts in low-incidence countries of tuberculosis.
OBJECTIVES: To analyze IGRA results and the effect of preventive chemotherapy on tuberculosis progression rates among recent contacts.
METHODS: Results from contact investigations at 26 centers in 10 European countries including testing for latent infection with M. tuberculosis by the QuantiFERON-TB Gold In-Tube (QFT) test or the T-SPOT.TB (TSPOT) were prospectively collected and analyzed.
MEASUREMENTS AND MAIN RESULTS: Among 5,020 contacts of 1,023 index cases, 25 prevalent secondary cases were identified at screening. Twenty-four incident cases occurred among 4,513 contacts during 12,326 years of cumulative follow-up. In those with a positive IGRA result, tuberculosis incidence was 0.2 (QFT) and 0 (TSPOT) per 100 patient-years when contacts received preventive chemotherapy versus 1.2 (QFT) and 0.8 (TSPOT) per 100 patient-years in those not treated (38 and 37 patients needed to be treated to prevent one case, respectively). Positive and negative predictive values were 1.9% (95% confidence interval [CI], 1.1-3.0) and 99.9% (95% CI, 99.7-100) for the QFT and 0.7% (95% CI, 0.1-2.6) and 99.7% (95% CI, 99.1-99.9) for the TSPOT.
CONCLUSIONS: Tuberculosis rarely developed among contacts, and preventive chemotherapy effectively reduced the tuberculosis risk among IGRA-positive contacts. Although the negative predictive value of IGRAs is high, the risk for the development of tuberculosis is poorly predicted by these assays.

Entities:  

Keywords:  IFN-γ release assay; LTBI; QuantiFERON; T-SPOT.TB; tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 25763458     DOI: 10.1164/rccm.201502-0232OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  36 in total

Review 1.  Update in Mycobacterium tuberculosis lung disease 2014.

Authors:  Paul Elkington; Alimuddin Zumla
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

2.  Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study.

Authors:  Jason R Andrews; Elisa Nemes; Michele Tameris; Bernard S Landry; Hassan Mahomed; J Bruce McClain; Helen A Fletcher; Willem A Hanekom; Robin Wood; Helen McShane; Thomas J Scriba; Mark Hatherill
Journal:  Lancet Respir Med       Date:  2017-02-16       Impact factor: 30.700

3.  Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.

Authors:  Elisa Nemes; Virginie Rozot; Hennie Geldenhuys; Nicole Bilek; Simbarashe Mabwe; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Alana Keyser; Asma Toefy; Yolundi Cloete; Frances Ratangee; Thomas Blauenfeldt; Morten Ruhwald; Gerhard Walzl; Bronwyn Smith; Andre G Loxton; Willem A Hanekom; Jason R Andrews; Maria D Lempicki; Ruth Ellis; Ann M Ginsberg; Mark Hatherill; Thomas J Scriba
Journal:  Am J Respir Crit Care Med       Date:  2017-09-01       Impact factor: 21.405

Review 4.  Tuberculosis susceptibility and protection in children.

Authors:  Robindra Basu Roy; Elizabeth Whittaker; James A Seddon; Beate Kampmann
Journal:  Lancet Infect Dis       Date:  2018-10-12       Impact factor: 25.071

Review 5.  Update in Tuberculosis/Pulmonary Infections 2015.

Authors:  Serena P Koenig; Jennifer Furin
Journal:  Am J Respir Crit Care Med       Date:  2016-07-15       Impact factor: 21.405

6.  Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.

Authors:  Marc Lipman; Mahdad Noursadeghi; Ibrahim Abubakar; Rishi K Gupta; Claire J Calderwood; Alexei Yavlinsky; Maria Krutikov; Matteo Quartagno; Maximilian C Aichelburg; Neus Altet; Roland Diel; Claudia C Dobler; Jose Dominguez; Joseph S Doyle; Connie Erkens; Steffen Geis; Pranabashis Haldar; Anja M Hauri; Thomas Hermansen; James C Johnston; Christoph Lange; Berit Lange; Frank van Leth; Laura Muñoz; Christine Roder; Kamila Romanowski; David Roth; Martina Sester; Rosa Sloot; Giovanni Sotgiu; Gerrit Woltmann; Takashi Yoshiyama; Jean-Pierre Zellweger; Dominik Zenner; Robert W Aldridge; Andrew Copas; Molebogeng X Rangaka
Journal:  Nat Med       Date:  2020-10-19       Impact factor: 53.440

7.  Evaluating latent tuberculosis infection diagnostics using latent class analysis.

Authors:  Jason E Stout; Yanjue Wu; Christine S Ho; April C Pettit; Pei-Jean Feng; Dolly J Katz; Smita Ghosh; Thara Venkatappa; Ruiyan Luo
Journal:  Thorax       Date:  2018-07-07       Impact factor: 9.139

8.  Lipoarabinomannan-Responsive Polycytotoxic T Cells Are Associated with Protection in Human Tuberculosis.

Authors:  Martin Busch; Christian Herzmann; Stephanie Kallert; Andreas Zimmermann; Christoph Höfer; Daniel Mayer; Sebastian F Zenk; Rainer Muche; Christoph Lange; Barry R Bloom; Robert L Modlin; Steffen Stenger
Journal:  Am J Respir Crit Care Med       Date:  2016-08-01       Impact factor: 21.405

9.  Evaluating UK National Guidance for Screening of Children for Tuberculosis. A Prospective Multicenter Study.

Authors:  Beate Kampmann; James A Seddon; James Paton; Zohreh Nademi; Denis Keane; Bhanu Williams; Amanda Williams; Sue Liebeschutz; Anna Riddell; Jolanta Bernatoniene; Sanjay Patel; Nuria Martinez; Paddy McMaster; Robindra Basu-Roy; Steven B Welch
Journal:  Am J Respir Crit Care Med       Date:  2018-04-15       Impact factor: 21.405

10.  Quantitative IFN-γ Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis. A Prospective Cohort Study.

Authors:  Rishi K Gupta; Marc Lipman; Charlotte Jackson; Alice J Sitch; Jo Southern; Francis Drobniewski; Jonathan J Deeks; Chuen-Yan Tsou; Chris Griffiths; Jennifer Davidson; Colin Campbell; Oliver Stirrup; Mahdad Noursadeghi; Heinke Kunst; Pranab Haldar; Ajit Lalvani; Ibrahim Abubakar
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.